cardiovascular system
N |
• no gross abnormalities in cardiac morphology or function
|
growth/size/body
N |
• healthy, without gross abnormalities
|
mortality/aging
N |
• viable
|
• significantly reduced alanine aminotransferase (ALT), serum aspartate aminotransferase (AST) and alkaline phosphatase (ALP) serum levels 6 and 24 h. after reperfusion following hepatic ischemia
(J:303068)
• significantly smaller necrotic areas in liver after hepatic ischemia/reperfusion (I/R)
(J:303068)
• significantly reduced CD11B+, LY6G+ and F4/80+ cell infiltration in liver 6 h. after reperfusion following hepatic ischemia
(J:303068)
• significantly reduced TNFA and CCL2 serum levels 24 h. after reperfusion following hepatic ischemia
(J:303068)
• significantly reduced apoptosis in liver after hepatic ischemia/reperfusion (I/R)
(J:303068)
• reduced cardiac hypertrophy and reduced increase in heart weight to body weight (HW/BW) and tibia length (HW/TL) and lung weight to body weight (LW/BW) ratios and cardiomyocyte cross-sectional area 4 weeks after aortic banding
(J:303651)
• reduced extent of cardiac interstitial and perivascular fibrosis 4 weeks after aortic banding
(J:303651)
• less cardiac ventricular dilation (reduced left ventricle end-systolic and end-diastolic dimension) and lower decrease of fractional shortening 4 weeks after aortic banding
(J:303651)
|
reproductive system
N |
• fertile
|